Advertisement

CardioVasc

, Volume 18, Issue 2, pp 39–42 | Cite as

Verbesserte Hämodynamik, Belastbarkeit und Symptomatik

Vorhofseptum-Shunt bei schwerer diastolischer Herzinsuffizienz

  • Gerd Hasenfuß
Fortbildung Schwerpunkt Kardiologie

Ausgehend von der Hypothese, dass ein erhöhter linksatrialer Druck (LA-Druck) pathophysiologisch bedeutsam bei der Herzinsuffizienz mit erhaltener Ejektionsfraktion ist, wurde ein Verfahren zur Senkung des LA-Drucks durch einen katheterbasierten implantierbaren interatrialen Shunt entwickelt. Bisher vorliegende Studien zeigen, dass dies sicher ist und den LA- und pulmonalarteriellen Druck anhaltend senkt. Eine anhaltend verbesserte Hämodynamik der Patienten unter Belastung und eine verbesserte klinische Symptomatik gehen damit einher.

Literatur

  1. 1.
    Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18–28CrossRefGoogle Scholar
  2. 2.
    Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH. Effects of treatment on exercise to- lerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol. 2011;57:1676–86CrossRefGoogle Scholar
  3. 3.
    Pandey A, Parashar A, Kumbhani D et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8:33–40CrossRefGoogle Scholar
  4. 4.
    Hasenfuß G, Burkhoff D, Kaye DM. A Shunt Device to Reduce Left Atrial Pressure. Cardiovasc Med. 2018, in pressGoogle Scholar
  5. 5.
    Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnomral right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. 2016:37:3293–302PubMedGoogle Scholar
  6. 6.
    Dorfs S, Zeh W, Hochholzer W et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J. 2014;35:3103–12CrossRefGoogle Scholar
  7. 7.
    Hasenfuß G, Hayward C, Burkhoff D et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicenter, open-label, single-arm, phase 1 trial. Lancet. 2016;387:1298–304CrossRefGoogle Scholar
  8. 8.
    Del Trigo M, Bergeron S, Bernier M et al. Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet. 2016;387:1290–97CrossRefGoogle Scholar
  9. 9.
    Feldman T, Mauri L, Kahwash R et al. A transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I): A phase 2, Randomized, Sham-controlled trial. Circulation. 2017 Nov 15; https://doi.org/10.1161/CIRCULATIONAHA.117.032094Google Scholar
  10. 10.
    Kaye DM, Hasenfuß G, Neuzil P et al. One-year outcomes after transcatheter insertion of an interatrial shunt device fort he management of heart failure with preserved ejection fraction. Cir Heart Fail. 2016;9:e003662; https://doi.org/10.1161/CIR-CHEARTFAILURE.116.003662CrossRefGoogle Scholar
  11. 11.
    Adamson PB, Abraham WT, Bourge RC et al. Wireless pulmonary artery pressure monitoring ruides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:935–44CrossRefGoogle Scholar
  12. 12.
    Zile MR, Bennett TD, El Hajj S et al. Intracardiac pressures measured using an implantable hemodynamic monitor — Relationship to mortality in patients with chronic heart failure. Circ Heart Fail. 2017;10:e003594; https://doi.org/10.1161/CIRCHEARTFAILURE.116.003594CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Kardiologie und Pneumologie, HerzzentrumUniversitätsmedizin GöttingenGöttingenDeutschland

Personalised recommendations